Literature DB >> 25788431

AML versus ICU: outcome of septic AML patients in an intensive care setting.

Christoph Sippel1, Young Kim, Anja Wallau, Peter Brossart, Ingo Schmidt-Wolf, Peter Walger.   

Abstract

PURPOSE: Intensive therapy regimens in patients with acute myeloid leukemia (AML) frequently result in sepsis and septic shock. In this study, we investigated the prognostic outcome of AML patients requiring intensive care treatment due to severe sepsis or septic shock.
DESIGN: We present a retrospective cohort study in a medical intensive care unit (ICU) of a university hospital that serves as a tertiary care center.
MATERIALS AND METHODS: Here we present data from 44 AML patients of our ICU with 29 requiring invasive mechanical ventilation due to sepsis and compared multiple clinical and laboratory parameters of ICU survivors and non-survivors.
RESULTS: Mean age was 59.5 years, the overall mortality rate was 41% (18/44), and the mortality rate among patients who received mechanical ventilation was 55% (16/29). The mortality rate among younger patients (aged 60 years or less) was 17% (3/18), while 58% of the older patients died (15/26). The mortality rate among younger patients who received mechanical ventilation was 23% (3/13) compared with 81% (13/16) of the older patients. The mean invasive ventilation time was 415 h in non-survivors compared with 667 h in survivors. No differences could be identified between survivors and non-survivors, concerning multiple laboratory parameters or AML prognostic and therapeutic parameters; our analysis, however, confirmed a statistically significant difference in the patients' age.
CONCLUSIONS: In previous studies, age was one of the most important prognostic factors in AML patients receiving mechanical ventilation due to severe sepsis or septic shock. In spite of improvements in diagnostic and treatment over the last couple of years, our study indicates that this fact still is true. However, the overall outcome has improved over the years due to improvements in intensive care medicine.

Entities:  

Mesh:

Year:  2015        PMID: 25788431     DOI: 10.1007/s00432-015-1955-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  18 in total

Review 1.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

Review 2.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

Authors:  Francesco Buccisano; Luca Maurillo; Maria Ilaria Del Principe; Giovanni Del Poeta; Giuseppe Sconocchia; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

3.  Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.

Authors:  Elihu H Estey
Journal:  Am J Hematol       Date:  2012-01       Impact factor: 10.047

4.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

Authors:  Roland B Walter; Megan Othus; Gautam Borthakur; Farhad Ravandi; Jorge E Cortes; Sherry A Pierce; Frederick R Appelbaum; Hagop A Kantarjian; Elihu H Estey
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

5.  Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study.

Authors:  Amanda L Roze des Ordons; Kris Chan; Imran Mirza; Derek R Townsend; Sean M Bagshaw
Journal:  BMC Cancer       Date:  2010-09-28       Impact factor: 4.430

Review 6.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

Review 7.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

8.  Survival of acute myelogenous leukemia patients requiring intubation/ventilatory support.

Authors:  L N Tremblay; R H Hyland; B D Schouten; P J Hanly
Journal:  Clin Invest Med       Date:  1995-02       Impact factor: 0.825

9.  Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

Authors:  Krzysztof Mrózek; Guido Marcucci; Deedra Nicolet; Kati S Maharry; Heiko Becker; Susan P Whitman; Klaus H Metzeler; Sebastian Schwind; Yue-Zhong Wu; Jessica Kohlschmidt; Mark J Pettenati; Nyla A Heerema; AnneMarie W Block; Shivanand R Patil; Maria R Baer; Jonathan E Kolitz; Joseph O Moore; Andrew J Carroll; Richard M Stone; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

10.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Authors:  C D Bloomfield; D Lawrence; J C Byrd; A Carroll; M J Pettenati; R Tantravahi; S R Patil; F R Davey; D T Berg; C A Schiffer; D C Arthur; R J Mayer
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

View more
  4 in total

1.  Reduce Mortality and Morbidity in Acute Myeloid Leukemia With Hyperleukocytosis With Early Admission in Intensive Care Unit: A Retrospective Analysis.

Authors:  Nathan Mottal; Nahema Issa; Pierre-Yves Dumas; Fabrice Camou; Mathieu Sauvezie; Francois-Xavier Gros; Titouan Cazaubiel; Gaelle Mourissoux; Harmony Leroy; Arnaud Pigneux; Olivier Guisset; Thibaut Leguay
Journal:  J Hematol       Date:  2020-10-01

2.  Code status transitions in patients with high-risk acute myeloid leukemia.

Authors:  Hannah R Abrams; Ryan D Nipp; Lara Traeger; Mitchell W Lavoie; Matthew J Reynolds; Nneka N Ufere; Annie C Wang; Kofi Boateng; Thomas W LeBlanc; Areej El-Jawahri
Journal:  Blood Adv       Date:  2022-07-26

3.  All-cause mortality in cancer patients treated for sepsis in intensive care units: a systematic review and meta-analysis.

Authors:  Lama Nazer; Maria A Lopez-Olivo; John A Cuenca; Wedad Awad; Anne Rain Brown; Aseel Abusara; Michael Sirimaturos; Rachel S Hicklen; Joseph L Nates
Journal:  Support Care Cancer       Date:  2022-10-10       Impact factor: 3.359

4.  Outcomes and Predictors of Mortality for Patients with Acute Leukemia Admitted to the Intensive Care Unit.

Authors:  Alan P Kraguljac; Danielle Croucher; Michael Christian; Narmin Ibrahimova; Vikram Kumar; Gabriella Jacob; Alex Kiss; Mark D Minden; Sangeeta Mehta
Journal:  Can Respir J       Date:  2016-06-30       Impact factor: 2.409

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.